GlassScriptPhysician profile
Meredith L Price
NPI 1548581432
$2,430.33
in general payments reported to CMS, 2019-2025
25 companies · $393 in 2025
The $393 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $104 · 2021: $366 · 2022: $723 · 2023: $62.98 · 2024: $404 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $860.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $532.91 | 2019-2025 | |
| Abbvie INC. | $506.83 | 2019-2025 | |
| Janssen Biotech, INC. | $247.70 | 2019-2022 | |
| Leo Pharma INC. | $201.92 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $114.48 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $112.56 | 2019-2022 | |
| Lilly USA, LLC | $88.57 | 2019-2023 | Taltz, Olumiant |
| Galderma Laboratories, L.P. | $87.49 | 2021-2025 | Dysport |
| Sun Pharmaceutical Industries INC. | $86.94 | 2021-2025 | Winlevi |
| Pfizer INC. | $70.73 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $51.17 | 2022-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $41.29 | 2021 | |
| Celgene Corporation | $38.51 | 2019 | |
| Incyte Corporation | $27.99 | 2022 | |
| Amgen INC. | $27.84 | 2024 | Otezla |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $26.72 | 2019 | |
| Vyne Pharmaceuticals INC. | $24.38 | 2021 | |
| Boston Scientific Corporation | $22.29 | 2025 | General - Pain Management |
| Dermira, INC. | $20.35 | 2019 | |
| Nabriva Therapeutics, Plc | $18.36 | 2022 | |
| Kyowa Kirin, INC. | $17.77 | 2022 | |
| Arcutis Biotherapeutics, INC. | $17.08 | 2025 | Zoryve |
| Taro Pharmaceuticals USA, INC. | $16.44 | 2019 | |
| Biofrontera INC. | $15.90 | 2020 | |
| Aclaris Therapeutics, INC. | $14.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.